Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIP2101 (Esomeprazole) vs Famotidine in Acute or Chronic Gastritis
NCT05024721Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in acute gastritis and chronic gastritis (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Improvement rate of erosion at 2 weeks. Started Aug 2021; status: completed.
02
Drugs
esomeprazole
03
Conditions
acute gastritischronic gastritis
Beyond the preview
Go deeper on NCT05024721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024721.